Patents Assigned to Universite Nice Sophia Antipolis
  • Patent number: 10376476
    Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: August 13, 2019
    Assignees: UNIVERSITE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Isabelle Mus-Veteau, Olivier Thomas, Marie-Aude Tribalat, Stephane Azoulay
  • Patent number: 10294289
    Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 21, 2019
    Assignees: Therachon SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Patent number: 10229299
    Abstract: A device for identifying an electrical appliance when it is powered up includes a current detector coupled to an electrical power supply cable of the electrical appliance, for detecting the passage of an electrical current in the cable and generating an electrical signal. A voltage generator converts the electrical signal at the output of the current detector into a direct voltage. An RFID circuit stores identification information, coupled to an antenna suitable for receiving and transmitting signals from and to an RFID reader. The device includes a control circuit coupled to the voltage generator and to the RFID circuit, the control circuit configured for producing a change of impedance of the antenna when the direct voltage is applied, the change of impedance allowing to transmit the identification information to the RFID reader.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 12, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE NICE-SOPHIA ANTIPOLIS
    Inventors: Robert Staraj, Jean-Marc Ribero, Mathieu Cosker
  • Patent number: 10155869
    Abstract: The invention concerns a compound formed by functionalized micro- or nanoparticles associated covalently with rheology-modifying polymers. The invention is characterized in that the functionalized micro- or nanoparticles are functionalized micro- or nanoparticles of cerium oxide (CeO2) having a nominal diameter of between 1 and 1500 nm. The rheology-adapting or -modifying polymers are selected from among non-associative or associative polymers. The invention is used in skin protection or decontamination.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: December 18, 2018
    Assignees: UNIVERSITE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'ORLEANS
    Inventors: Sonia Amigoni, Denis Josse, Thierry Devers, Arnaud Zenerino, Frédéric Guittard, Elisabeth Taffin de Givenchy, Cécile Bignon
  • Patent number: 10126163
    Abstract: A fiber optic sensor for detecting an excitation in proximity to a fiber optic assembly, the excitation inducing a modulation of the phase of an optical signal propagating in the fiber optic assembly, the sensor comprises: a laser assembly emitting at least one laser beam; a fiber optic assembly; an optical system configured to: inject at least one portion of the laser beam; generate at least one laser signal beam issued from the laser beam injected into and propagated in the fiber assembly; generate at least one reference beam from the laser beam or the signal beam; produce at least one interference zone corresponding to the interference between a portion of the reference beam and a portion of the interference signal beam corresponding to the interference between a portion of the reference beam and a portion of the signal beam; a digital holography assembly comprising: a liquid-crystal spatial light modulator; a video camera configured to receive the interference zone and to transcribe it electrically to the
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: November 13, 2018
    Assignees: THALES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE NICE SOPHIA-ANTIPOLIS
    Inventors: Jean-Pierre Huignard, Umberto Bortolozzo, Daniel Dolfi, Stéphanie Molin, Arnaud Peigne, Stefania Residori
  • Publication number: 20180148494
    Abstract: The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.
    Type: Application
    Filed: January 7, 2016
    Publication date: May 31, 2018
    Applicants: TheAchon, Inserm (Institut National de la Sante et de la Recherche Medicale), Universite Nice Sophia Antipolis
    Inventors: Elvire GOUZE, Stéphanie GARCIA
  • Patent number: 9981982
    Abstract: The invention relates to a multilayer superoleophobic and/or superhydrophobic material comprising: ? on the one hand, a first constituent that is a conductive substrate or a substrate that has previously been rendered conductive (1): ? the surface of which is modified by chemical and/or physical treatment (2) and that incorporates a first adhesion-promoting conductive layer (3); ? or that incorporates a first adhesion-promoting conductive layer (3); ? and, on the other hand, at least one other constituent that is a superoleophobic and/or superhydrophobic polymer or copolymer layer (4, 5 or 6) composed of one or more monomers based on an aromatic or heteroaromatic ring substituted by one or more fluorocarbon and/or hydrocarbon chains. It is characterized in that the various constituents of said material comply with an increasing hydrophobicity gradient between the first layer deposited on the conductive substrate or substrate previously rendered conductive (1) and the last layer of said material.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 29, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Elena Celia, Jeanne Hélène Suzanne Tarrade, Thierry Darmanin, Frédéric Guittard
  • Publication number: 20170326076
    Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to the use of a panicein or a derivative thereof, to decrease or inhibit, in vitro or ex vivo, the Patched receptor drug efflux activity, in particular the chemotherapeutic drug efflux activity and chemotherapy resistance. The present disclosure further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The compound of the invention can indeed be advantageously used, in combination with at least one chemotherapeutic drug, for treating cancer, for preventing cancer metastasis and/or for preventing cancer recurrence in a subject.
    Type: Application
    Filed: October 26, 2015
    Publication date: November 16, 2017
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: ISABELLE MUS-VETEAU, OLIVIER THOMAS, MARIE-AUDE TRIBALAT, STÉPHANE AZOULAY
  • Patent number: 9708608
    Abstract: The present invention relates to an in vitro or ex vivo method for producing a population of pancreatic beta-cells, comprising the step of inhibiting the expression or the activity of Arx in a population of pancreatic alpha-cells. The present invention also relates to method for inducing the conversion of pancreatic alpha-cells in pancreatic beta-cells in a patient in need thereof.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: July 18, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientific (CNRS), Universite Nice Sophia Antipolis
    Inventors: Patrick Collombat, Keith Al-Hasani, Monica Courtney, Nouha Ben-Ohtman, Elisabet Gjernes, Ahmed Mansouri
  • Patent number: 9637553
    Abstract: The present invention relates to antibodies anti-sPLA2-IIA and uses thereof.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: May 2, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Gerard Lambeau, Emmanuel Valentin, Melanie Rennou
  • Patent number: 9567310
    Abstract: The present invention relates to compound of general formula (1) wherein R1 represents C6-C10 aryl comprising one or two fused rings, wherein from 2 to 5 carbon atoms may be replaced with a heteroatom selected from O, S and NR6, and eventually substituted with from 5 to 11 substituents selected from R6, halo, CN, NO2, CF3, OCF3, COOR6, OCOR6, SO2NR6R7, CONR6R7, NR6R7, NR6COR7, (CH2)p—NR6R7, (CH2)p—OR6 and (CH2)pSR6, as well as, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: February 14, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHARCHE MEDICALE), UNIVERSITE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Stephane Rocchi, Robert Ballotti, Rachid Benhida, Michael Cerezo, Maria Duca, Jean-Patrick Joly
  • Publication number: 20160298115
    Abstract: The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.
    Type: Application
    Filed: March 22, 2016
    Publication date: October 13, 2016
    Applicants: Centre National de la Recherche Scientifique, l'Université Nice Sophia Antipolis
    Inventors: Marcel SCHEIDELER, Michael KARBIENER, Ez-Zoubir AMRI, Gérard AILHAUD, Christian DANI
  • Publication number: 20160152832
    Abstract: The invention concerns a compound formed by functionalized micro- or nanoparticles associated covalently with rheology-modifying polymers. The invention is characterized in that the functionalized micro- or nanoparticles are functionalized micro- or nanoparticles of cerium oxide (CeO2) having a nominal diameter of between 1 and 1500 nm. The rheology-adapting or -modifying polymers are selected from among non-associative or associative polymers. The invention is used in skin protection or decontamination.
    Type: Application
    Filed: July 18, 2014
    Publication date: June 2, 2016
    Applicants: UNIVERSITE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'ORLEANS
    Inventors: Sonia Amigoni, Denis Josse, Thierry Devers, Arnaud Zenerino, Frédéric Guittard, Elisabeth Taffin de Givenchy, Cécile Bignon
  • Patent number: 9320756
    Abstract: The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: April 26, 2016
    Assignees: Centre National de la Recherche Scientifique, l'Université Nice Sophia Antipolis
    Inventors: Marcel Scheideler, Michael Karbiener, Ez-Zoubir Amri, Gérard Ailhaud, Christian Dani
  • Publication number: 20160096845
    Abstract: The invention relates to a multilayer superoleophobic and/or superhydrophobic material comprising: on the one hand, a first constituent that is a conductive substrate or a substrate that has previously been rendered conductive (1): the surface of which is modified by chemical and/or physical treatment (2) and that incorporates a first adhesion-promoting conductive layer (3); or that incorporates a first adhesion-promoting conductive layer (3); and, on the other hand, at least one other constituent that is a superoleophobic and/or superhydrophobic polymer or copolymer layer (4, 5 or 6) composed of one or more monomers based on an aromatic or heteroaromatic ring substituted by one or more fluorocarbon and/or hydrocarbon chains. It is characterized in that the various constituents of said material comply with an increasing hydrophobicity gradient between the first layer deposited on the conductive substrate or substrate previously rendered conductive (1) and the last layer of said material.
    Type: Application
    Filed: May 21, 2014
    Publication date: April 7, 2016
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Elena Celia, Jeanne Hélène Suzanne Tarrade, Thierry Darmanin, Frédéric Guittard
  • Publication number: 20150374610
    Abstract: The invention concerns a compound formed by functionalised micro- or nanoparticles covalently associated with rheology-modifying polymers. The invention is characterised in that the functionalised micro- or nanoparticles are functionalised inorganic or metal oxide micro- or nanoparticles, in particular aluminium oxide (Al2O3), copper oxide (CuO), iron oxide (Fe3O4 or ?-Fe2O3), magnesium oxide (MgO), silica (SiO2), titanium dioxide (TiO2) or zinc oxide (ZnO), having a nominal diameter of between 1 and 1500 nm; and in that the rheology-modifying or -adapting polymers are chosen from non-associative polymers or associative polymers. The invention applies to protection or decontamination of the skin.
    Type: Application
    Filed: February 21, 2014
    Publication date: December 31, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Frédéric Guittard, Sonia Amigoni, Elisabeth Taffin de Givenchy, Arnaud Zenerino, Denis Josse
  • Patent number: 9173892
    Abstract: Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described. Finally, a method for inhibiting the in vitro cell proliferation including the placement of an in vitro cell in contact with the derivatives and methods for synthesis of said derivatives and methods for synthesis of the derivatives are described.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: November 3, 2015
    Assignees: Universite Nice Sophia Antipolis, Centre National De La Recherche Scientifique, Institut National De La Sante De La Recherche Medicale
    Inventors: Rachid Benhida, Patrick Auberger, Vincent Malnuit, Mohsine Driowya, Alexandre Puissant, Guillaume Robert
  • Publication number: 20150182550
    Abstract: A method of treating cancer is described. The method includes administering to a person in need thereof an effective amount of a ligand selected from the group consisting of shRNA, igmesine, and (+) pentazocine, wherein the ligand modulates a channel macrocomplex comprising a sigma-1 receptor and an ion channel.
    Type: Application
    Filed: March 10, 2015
    Publication date: July 2, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, UNIVERSITE NICE SOPHIA ANTIPOLIS
    Inventors: Olivier Soriani, Mauro Franck Borgese, Sonia Martial
  • Publication number: 20150094217
    Abstract: The invention relates to an in vitro analysis method for predicting resistance to azacitidine treatment in a patient, using the BCL2L10 protein contained in a sample of biological fluid taken from said patient, and also biological molecules which specifically bind the BCL2L10 protein. It is characterized in that a sample of biological fluid is recovered from a patient; the percentage of total cells in said biological fluid expressing the BCL2L10 protein is calculated; this calculated percentage is compared with a reference threshold value, this threshold value being between 20% and 60%; and resistance to azacitidine treatment is diagnosed in a patient who has a percentage of cells expressing the BCL2L10 protein in said biological fluid which is greater than said reference value.
    Type: Application
    Filed: February 28, 2013
    Publication date: April 2, 2015
    Applicants: UNIVERSITÉ NICE SOPHIA ANTIPOLIS, CENTRE HOSPITALIER UNIVERSITAIRE DE NICE
    Inventors: Thomas Cluzeau, Patrick Auberger, Guillaume Robert, Frédéric Luciano
  • Patent number: 8895520
    Abstract: A method of treatment of a human patient suffering from myeloid neoplasias, includes administrating a therapeutically effective amount of 5-aminoimidazole-4-carboxamide (acadesine), acadesine precursors or acadesine derivatives.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: November 25, 2014
    Assignees: Universite Nice Sophia Antipolis, Centre Hospitalier Universitaire de Nice, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Thomas Cluzeau, Patrick Auberger, Guillaume Robert